Comparison · NCT01545817-sae
Pazopanib vs Everolimus: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pazopanib vs Everolimus: serious adverse events. Trial comparisons, record NCT01545817-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01545817-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.635 | 0.521 | 0.736 | wilson | |
| Risk in group 2 | 0.421 | 0.279 | 0.578 | wilson | |
| Risk difference, group 1 minus group 2 | 0.214 | 0.0201 | 0.388 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.51 | 1 | 2.27 | log | |
| Odds ratio, group 1 over group 2 | 2.39 | 1.08 | 5.32 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Pazopanib than on Everolimus | 4.67 | 2.57 | 49.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pazopanib | All patients were assigned to first-line treatment with pazopanib once daily. Pazopanib was supplied as 200 mg and 400 mg tablets. Pazopanib was administered once daily at the approved recommended dose of 800 mg/day (two 400 mg tablets, treatment taken once daily). The 200 mg tablets were provided to patients who needed dose adjustment. | 47 | 74 | EG000 |
| Group 2 | Everolimus | Patients who progressed during or within 6 months after stopping pazopanib treatment were eligible to then receive everolimus once daily (10 mg) as second-line treatment.~Everolimus was supplied to the study sites as 5 mg and 10 mg tablets. The 5 mg tablets were provided to patients who needed dose adjustments. | 16 | 38 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events for each intervention were assessed from the time of first dose of treatment to approximately one month after discontinuation of the last dose of treatment, up to 4 years.
Source ClinicalTrials.gov
Trial
- Title
- Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
- NCT number
- NCT01545817
- Phases
- PHASE2
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pazopanib followed by everolimus
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2019-10-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01545817?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01545817-sae